|
1
|
Bandarchi B, Jabbari CA, Vedadi A and
Navab R: Molecular biology of normal melanocytes and melanoma
cells. J Clin Pathol. 66:644–648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cary LA and Guan JL: Focal adhesion kinase
in integrin-mediated signaling. Front Biosci. 4:D102–D113. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schlaepfer DD, Hauck CR and Sieg DJ:
Signaling through focal adhesion kinase. Prog Biophys Mol Biol.
71:435–478. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee BY, Timpson P, Horvath LG and Daly RJ:
FAK signaling in human cancer as a target for therapeutics.
Pharmacol Ther. 146:132–149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McLean GW, Carragher NO, Avizienyte E,
Evans J, Brunton VG and Frame MC: The role of focal-adhesion kinase
in cancer-a new therapeutic opportunity. Nat Rev Cancer. 5:505–515.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sulzmaier FJ, Jean C and Schlaepfer DD:
FAK in cancer: Mechanistic findings and clinical applications. Nat
Rev Cancer. 14:598–610. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brusegan C, Pistocchi A, Frassine A, Della
Noce I, Schepis F and Cotelli F: Ccdc80-l1 Is involved in axon
pathfinding of zebrafish motoneurons. PLoS One. 7:e318512012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferraro A, Schepis F, Leone V, Federico A,
Borbone E, Pallante P, Berlingieri MT, Chiappetta G, Monaco M,
Palmieri D, et al: Tumor suppressor role of the CL2/DRO1/CCDC80
gene in thyroid carcinogenesis. J Clin Endocrinol Metab.
98:2834–2843. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Visconti R, Schepis F, Iuliano R,
Pierantoni GM, Zhang L, Carlomagno F, Battaglia C, Martelli ML,
Trapasso F, Santoro M and Fusco A: Cloning and molecular
characterization of a novel gene strongly induced by the adenovirus
E1A gene in rat thyroid cells. Oncogene. 22:1087–1097. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bommer GT, Jäger C, Dürr EM, Baehs S,
Eichhorst ST, Brabletz T, Hu G, Fröhlich T, Arnold G and Kress DC:
DRO1, a gene down-regulated by oncogenes, mediates growth
inhibition in colon and pancreatic cancer cells. J Biol Chem.
280:7962–7975. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Herbst A, Bayer C, Wypior C and Kolligs
FT: DRO1 sensitizes colorectal cancer cells to receptor-mediated
apoptosis. Oncol Lett. 2:981–984. 2011.PubMed/NCBI
|
|
12
|
Ferragud J, Avivar-Valderas A, Pla A, De
Las Rivas J and Font de Mora J: Transcriptional repression of the
tumor suppressor DRO1 by AIB1. FEBS Lett. 585:3041–3046. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lan Y and Hua ZC: Construction of stable
focal adhesion kinase knockdown cell line and preliminary study of
its properties. Yao Xue Xue Bao. 47:1128–1133. 2012.(In Chinese).
PubMed/NCBI
|
|
15
|
Singhai R, Patil VW, Jaiswal SR, Patil SD,
Tayade MB and Patil AV: E-Cadherin as a diagnostic biomarker in
breast cancer. N Am J Med Sci. 3:227–233. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khan P, Manna A, Saha S, Mohanty S,
Mukherjee S, Mazumdar M, Guha D and Das T: Aspirin inhibits
epithelial-to-mesenchymal transition and migration of oncogenic
K-ras-expressing non-small cell lung carcinoma cells by
down-regulating E-cadherin repressor Slug. BMC Cancer. 16:392016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Venza M, Visalli M, Catalano T, Biondo C,
Beninati C, Teti D and Venza I: DNA methylation-induced E-cadherin
silencing is correlated with the clinicopathological features of
melanoma. Oncol Rep. 35:2451–2460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cui T, Srivastava AK, Han C, Yang L, Zhao
R, Zou N, Qu M, Duan W, Zhang X and Wang QE: XPC inhibits NSCLC
cell proliferation and migration by enhancing E-Cadherin
expression. Oncotarget. 6:10060–10072. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Russo AE, Torrisi E, Bevelacqua Y,
Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F and
Malaponte G: Melanoma: Molecular pathogenesis and emerging target
therapies (Review). Int J Oncol. 34:1481–1489. 2009.PubMed/NCBI
|
|
20
|
Shoo BA and Kashani-Sabet M: Melanoma
arising in African-, Asian-, Latino- and Native-American
populations. Semin Cutan Med Surg. 28:96–102. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rigel DS and Carucci JA: Malignant
melanoma: Prevention, early detection, and treatment in the 21st
century. CA Cancer J Clin. 50:215–240. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rangel J, Torabian S, Shaikh L, Nosrati M,
Baehner FL, Haqq C, Leong SP, Miller JR III, Sagebiel RW and
Kashani-Sabet M: Prognostic significance of nuclear receptor
coactivator-3 overexpression in primary cutaneous melanoma. J Clin
Oncol. 24:4565–4569. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Font de Mora J and Brown M: AIB1 is a
conduit for kinase-mediated growth factor signaling to the estrogen
receptor. Mol Cell Biol. 20:5041–5047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ito T, Kamijo S, Izumi H, Kohno K, Amano J
and Ito K: Alteration of Y-box binding protein-1 expression
modifies the response to endocrine therapy in estrogen
receptor-positive breast cancer. Breast Cancer Res Treat.
133:145–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
